Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31082989 | 0.89 | KCNH2 (0.39) | KDM1AMAOB | |
| SCHEMBL25106026 | 0.89 | KCNH2 (0.39) | KDM1AMAOB | |
| SCHEMBL31083073 | 0.89 | KCNH2 (0.39) | KDM1AMAOB | |
| SCHEMBL30675007 | 0.86 | KDM1A (0.42) | KDM1AMAOBMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL28165037 | 0.78 | KDM1A (0.47) | KDM1AMAOBMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL5968409 | 0.78 | ALDH1A1 (0.52) | KDM1AMAOBMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL24032965 | 0.78 | KDM1A (0.47) | KDM1AMAOBMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL12802126 | 0.77 | MAPK1 (0.33) | KDM1AMAOBMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL4877708 | 0.76 | KCNH2 (0.42) | KDM1AMAOBMAPK1 | |
| SCHEMBL2199980 | 0.76 | KCNH2 (0.42) | KDM1AMAOBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | claimed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | claimed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | KDM1A 387/4885MAOB 1961/4885MAPK1 2918/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | KDM1A 387/4885MAOB 1961/4885MAPK1 2918/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | KDM1A 387/4885MAOB 1961/4885MAPK1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.